BACKGROUND: Chemotherapy-induced @entity390 and @entity391 adversely affects the quality of life of @entity1 who receive chemotherapy via intravenous infusion or transcatheter arterial chemoembolization (TACE). This study aimed to investigate the clinical effects of transcutaneous electrical acupoint stimulation (TEAS) on @entity390 and @entity391 after TACE. METHODS: A total of 142 @entity1 who received TACE with @entity900 for primary or metastatic @entity96 were assigned to the active-acupuncture (n  =  72) or placebo-acupuncture (n  =  70) groups using a covariate-adaptive randomization at a ratio of 1:1. The acupoints Hegu ( @entity9154 ), Neiguan (P6), and Zusanli (ST36) were stimulated twice daily for 6  days. The effects of TEAS on @entity390 and @entity391 were assessed by using occurrence rate and severity of these symptoms. @entity448 scale and M. D. Anderson Symptom Inventory (MDASI) scores were secondary endpoints and were used to assess the effect of TEAS on @entity1 appetite and quality of life. The safety of the treatments was also monitored. RESULTS: Between the two groups, the differences in occurrence rates and severities of @entity390 and @entity391 after TACE were not significant (all P  >  0.05). From the second day after TACE, @entity448 scores were significantly lower in the active-acupuncture group than in the placebo-acupuncture group and continued to decrease over time with treatment (all P values less than 0.01). On days 0, 1, and 2, the mean MDASI scores for the active-acupuncture group were slightly lower than those for the placebo-acupuncture group, but the differences were not statistically significant (all P  >  0.05). No significant differences were found between the two groups in the occurrence rate of any adverse event (P  >  0.05). CONCLUSION: TEAS appears to be a safe and effective therapy to relieve @entity1 ' gastrointestinal discomfort after chemotherapy. Trial registration NCT01895010. Registered 21 June 2013.

Effect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced @entity390 and XXXX : a single-blind, randomized, controlled trial.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity9154 :: ('643418', 'Gene') :: ['LI4'] @entity96 :: ('MESH:D008113', 'Disease') :: ['liver cancer'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity448 :: ('MESH:D000855', 'Disease') :: ['Anorexia', 'anorexia']
@entity391 :: (MESH:D014839,Disease) :: ['vomiting']
